Halozyme Therapeutics to present its product development pipeline

Download PDF Copy

Sep 15 2009

Halozyme Therapeutics, Inc. (Nasdaq:HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced its participation in the UBS Global Life Sciences Conference to be held on September 21-23, 2009 in New York City. Jonathan Lim, M.D., President and CEO, is scheduled to present an overview of Halozyme and its product development pipeline on Tuesday, September 22, 2009 at 3:00 p.m. EDT (12:00 p.m. PDT).

To listen to the audio webcast of the presentation live or after the event, please visit the company’s Web site. The replay will be available for 30 days after the presentation.

http://www.halozyme.com/

Posted in: Pharmaceutical News

Comments (0)

Download PDF Copy

Suggested Reading

Once-monthly obesity injection shows double-digit weight loss in major clinical trial

How microRNA is transforming science: From discovery to diagnostics

Scaling B-cell cloning workflows for antibody development

Lasting COVID-19 vulnerability in childhood cancer survivors

New nanobody-liposome combo stops lung cancer growth and delivers targeted chemotherapy

Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

Scientists use AI to build mutation-proof antibodies for SARS-CoV-2

Experts chart path to bring microbiome science into routine clinical care

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

(Logout)

Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.